The city of Santa Monica, California, currently has 78 active clinical trials seeking participants for Cancer research studies.
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Sarcoma Oncology, Santa Monica, California
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participants in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: UCLA Health (Santa Monica Cancer Care), Santa Monica, California
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: UCLA Hematology/Oncology-Santa Monica, Santa Monica, California
Conditions: Breast Cancer
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: St. John's Cancer Center, Santa Monica, California
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Evaluation of the PhageTech Virus BioResistor
Recruiting
To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2021
Locations: Providence Saint John's Health Center and the Saint John's Cancer Institute, Santa Monica, California
Conditions: Bladder Cancer